Stock Analysis

CapMan Oyj And 2 Other Stocks Estimated To Be Below Intrinsic Value

OM:SUS
Source: Shutterstock

As global markets continue to navigate the complexities of rising inflation and interest rate expectations, U.S. stock indexes are climbing toward record highs, with growth stocks outpacing value shares. In this environment, identifying undervalued stocks can be a strategic approach for investors looking to capitalize on potential discrepancies between market prices and intrinsic values.

Top 10 Undervalued Stocks Based On Cash Flows

NameCurrent PriceFair Value (Est)Discount (Est)
Provident Financial Services (NYSE:PFS)US$18.66US$36.9949.6%
Hancom (KOSDAQ:A030520)₩24650.00₩49094.7949.8%
Nuvoton Technology (TWSE:4919)NT$96.10NT$191.3149.8%
Smurfit Westrock (NYSE:SW)US$55.30US$109.7449.6%
IDP Education (ASX:IEL)A$12.12A$24.1149.7%
Solum (KOSE:A248070)₩17610.00₩34899.0049.5%
Com2uS (KOSDAQ:A078340)₩48200.00₩96034.2649.8%
Saipem (BIT:SPM)€2.341€4.6749.8%
Likewise Group (AIM:LIKE)£0.185£0.3749.8%
Constellium (NYSE:CSTM)US$9.24US$18.2749.4%

Click here to see the full list of 924 stocks from our Undervalued Stocks Based On Cash Flows screener.

Below we spotlight a couple of our favorites from our exclusive screener.

CapMan Oyj (HLSE:CAPMAN)

Overview: CapMan Oyj is a leading Nordic private assets management and investment firm specializing in growth capital, middle market buyouts, and infrastructure investments, with a market cap of €346.28 million.

Operations: CapMan Oyj generates revenue primarily through its Management Company Business, which accounts for €56.76 million, and its Service Business segment, contributing €0.27 million.

Estimated Discount To Fair Value: 19.4%

CapMan Oyj, trading at €1.96, is undervalued by 19.4% compared to its fair value of €2.43 based on discounted cash flow analysis. The company's earnings are expected to grow significantly at 29% annually over the next three years, outpacing the Finnish market's growth rate of 11.9%. However, despite strong revenue growth and a substantial increase in net income last year, dividend sustainability remains a concern due to insufficient coverage by earnings or free cash flows.

HLSE:CAPMAN Discounted Cash Flow as at Feb 2025
HLSE:CAPMAN Discounted Cash Flow as at Feb 2025

Surgical Science Sweden (OM:SUS)

Overview: Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training across Europe, the Americas, Asia, and other international markets, with a market cap of SEK9.63 billion.

Operations: The company's revenue is derived from two segments: Industry/OEM, generating SEK419.66 million, and Educational Products, contributing SEK440.17 million.

Estimated Discount To Fair Value: 38.9%

Surgical Science Sweden, trading at SEK 188.8, is undervalued by 38.9% against its fair value of SEK 308.96 based on discounted cash flow analysis. Recent collaborations, such as integrating simulation software with Intuitive's da Vinci systems and expanding into defense markets with a US$4.7 million order, bolster growth prospects. Despite a low future return on equity forecast of 6.4%, earnings are expected to grow significantly at over 32% annually, surpassing Swedish market averages.

OM:SUS Discounted Cash Flow as at Feb 2025
OM:SUS Discounted Cash Flow as at Feb 2025

West Holdings (TSE:1407)

Overview: West Holdings Corporation, along with its subsidiaries, operates in the renewable energy sector both in Japan and internationally, with a market cap of ¥69.72 billion.

Operations: The company's revenue segments include renewable energy operations both domestically and globally.

Estimated Discount To Fair Value: 38.3%

West Holdings, priced at ¥1758, is undervalued by over 20% compared to its fair value of ¥2847.77 according to discounted cash flow analysis. The company anticipates revenue growth of 12.6% annually, outpacing the Japanese market's 4.2%. However, its debt isn't well covered by operating cash flow and a volatile share price has been observed recently. Earnings are projected to grow at 14.9% per year, exceeding market averages but dividends remain inadequately covered by free cash flows.

TSE:1407 Discounted Cash Flow as at Feb 2025
TSE:1407 Discounted Cash Flow as at Feb 2025

Where To Now?

Want To Explore Some Alternatives?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About OM:SUS

Surgical Science Sweden

Develops and markets virtual reality simulators for evidence-based medical training in Europe, North and South America, Asia, and internationally.

Flawless balance sheet and slightly overvalued.

Similar Companies